Epredia and Mindpeak Announce Distribution Agreement for AI-Based Image Recognition Software
As cancer cases rise and diagnostic processes become more complex, pathology laboratories face increasing pressure to speed up processes and reduce costs. Epredia, a global leader in precision cancer diagnostics and a subsidiary of PHC Holdings Corporation (TSE: 6523), and Mindpeak, a leading provider of artificial intelligence (AI) solutions for clinical and research pathology, have announced a distribution agreement to bring Mindpeak’s AI-based image recognition software to Epredia’s digital pathology customers in the European Union.
“Epredia is committed to providing the right tool at the right time to help pathology labs deliver accurate, efficient diagnoses of cancer, so patients can get the care they need,” said Steven Lynum, President of Epredia. “Our entire workflow of solutions, from stains to digital scanners, works together to create the high-quality tissue samples needed for diagnosis, and AI image recognition software has the potential to bring a new level of speed, accuracy, and reliability to that process.”
Key Insights at a Glance
- AI Technology: Mindpeak’s AI technology delivers instant, pixel-level analysis of digital images of tissue samples, enabling objective and reproducible assessments.
- Workflow Efficiency: The tools are designed to reduce variability, support decision-making, and improve workflow efficiency.
- Data Privacy: Mindpeak’s AI solutions do not require cloud connectivity, offering data privacy and security for both clinical and research environments.
- Future Integration: Epredia intends to explore integration of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution workflow.
The Pressure on Pathology Labs
Just as a surgeon relies on precise instruments, pathology laboratories depend on advanced tools to handle the growing complexity of cancer diagnostics. With the increasing number of cancer cases, labs are under immense pressure to deliver faster and more accurate results while managing costs. Mindpeak’s AI technology addresses this challenge by providing instant, pixel-level analysis of digital images, reducing variability and improving workflow efficiency. This is crucial for ensuring that patients receive timely and accurate diagnoses, which can significantly impact their treatment outcomes.
The Urgency of AI Integration
Like a conductor coordinating an orchestra, Epredia is orchestrating a seamless integration of advanced technologies to enhance cancer diagnostics. The partnership with Mindpeak is a critical step in this direction, as it brings cutting-edge AI solutions to pathology labs in the European Union. This integration is not just about improving current processes; it is about setting the stage for a future where AI-driven diagnostics are the norm. The next phase will involve exploring the integration of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution, which could revolutionize the way pathologists work.
Epredia Mobilizes for AI-Driven Diagnostics
Epredia is committed to providing comprehensive solutions for precision cancer diagnostics. Under the new distribution agreement, Epredia will offer Mindpeak’s AI software for clinical diagnostics, translational research, and pharmaceutical development. This move aligns with Epredia’s mission to improve lives by enhancing cancer diagnostics for patients around the world. The company’s portfolio of end-to-end pathology solutions, including pathology consumables, instruments, and advanced image management systems, will be further strengthened by the addition of Mindpeak’s AI technology. Looking ahead, Epredia plans to explore the integration of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution, which could enable a seamless workflow and streamlined data exchange.
Future Outlook
The partnership between Epredia and Mindpeak is like a well-choreographed dance, where each step is carefully planned to achieve a common goal. By integrating AI into their digital pathology solutions, Epredia is paving the way for more efficient and accurate cancer diagnostics. This collaboration is not just a strategic move; it is a commitment to advancing the field of pathology and improving patient outcomes. The future integration of Mindpeak’s AI solutions into the Epredia E1000 Dx Digital Pathology Solution is a clear indication of the company’s dedication to innovation and excellence.
Conclusion
The partnership between Epredia and Mindpeak represents a significant step forward in the field of digital pathology. By leveraging AI technology, Epredia is addressing the growing challenges faced by pathology labs and enhancing the accuracy and efficiency of cancer diagnostics. This collaboration underscores Epredia’s commitment to providing the best tools and solutions to improve patient care. Join the conversation in the comments below.
About Epredia
Epredia is a global leader in the anatomical pathology field, providing comprehensive solutions for precision cancer diagnostics and tissue diagnostics. Powered by key brands, including Erie Scientific, Menzel-Gläser, Microm, Shandon, and Richard-Allan Scientific, Epredia’s portfolio includes microscope slides, instruments and consumables. Epredia was established following the acquisition of Thermo Fisher Scientific’s Anatomical Pathology business by PHC Holdings (TSE 6523) in 2019. Epredia has manufacturing sites in the United States, the United Kingdom, Italy, France, and China with a total of around 1,200 employees. Epredia is committed to achieving its mission to improve lives by enhancing cancer diagnostics for patients around the world.
About PHC Holdings Corporation (PHC Group)
PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex Corporation and Mediford Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries and regions.
About Mindpeak
Founded in 2018, Mindpeak is a global innovator in AI-driven digital pathology solutions. The company develops cutting-edge algorithms that support pathologists in routine diagnostics, focusing on automating tissue analysis for faster, more accurate results. Mindpeak’s platform is designed to enhance productivity and diagnostic confidence in clinical labs, helping to improve patient outcomes in cancer care.
Source link: https://www.businesswire.com/
